Amgen’s $3.7B ChemoCentryx acquisition adds a new piece to autoimmune strategy

Putting puzzle pieces together on sky background with sunlight merger

Amgen’s drug portfolio boasts several biologic drugs that are blockbuster sellers. In acquiring ChemoCentryx for $3.7 billion, the pharmaceutical giant gains a company entirely focused on developing small molecule alternatives to biologic medicines.